GHK-Cu is a copper tripeptide, and its neuroprotection evidence is still preclinical

The short version

GHK-Cu is three amino acids — glycine, histidine and lysine — holding one copper atom. Your own blood carries it, and the amount drops as you age, from about 200 ng/mL at twenty to about 80 ng/mL at sixty ^[3]. In lab dishes it tells skin cells to make more collagen, the protein that keeps skin firm ^[1]. That is why it turns up in face creams under the label Copper Tripeptide-1.

The headline for this site is the brain research, and the honest headline is that it is small. Two 2023 preprints — papers posted online before peer review — gave mice a nose-drop version and saw better maze scores and less brain-damage signal ^[7][8]. A 2024 lab study showed the peptide mopping up loose copper and zinc that otherwise kill nerve cells in culture ^[15]. No human neurological trial has been published. Nothing here is a dose or a treatment plan, and what people report — including the downsides — is on the effects page.

What Is a Copper Peptide?

A copper peptide is a short chain of amino acids that grips a copper ion. Copper is a working metal in the body: enzymes use it to knit collagen and elastin fibres together and to neutralise reactive oxygen. Loose copper is destructive, so the body keeps it bound. A copper peptide is a carrier — it holds the metal in a stable, usable form and hands it to cells that need it. GHK-Cu is the best-studied example.

GHK Copper Peptide: The Endogenous Tripeptide Behind the Name

GHK copper peptide is not a synthetic invention. The Gly-His-Lys sequence sits inside the alpha-2(I) chain of type I collagen and inside SPARC/osteonectin, and it is found free in human plasma, saliva and urine. Loren Pickart isolated it in 1973 as the plasma factor that made aged human liver tissue synthesise proteins the way younger tissue does.

The implied model is a damage signal. Collagen breaks; fragments release; a fragment that happens to chelate copper reaches the surrounding cells and turns on the repair programme. The 2008 tissue-remodeling review sets out the full profile that follows: increased synthesis of collagen, elastin, metalloproteinases, anti-proteases, VEGF, FGF-2, NGF, neurotrophins 3 and 4 and erythropoietin, with suppression of free radicals, thromboxane, oxidising-iron release, TGF-beta-1, TNF-alpha and protein glycation, plus chemoattraction of macrophages, mast cells and capillary cells into the wound ^[6].

The age curve is the part that drives the anti-aging framing. Plasma GHK falls from roughly 200 ng/mL at age twenty to roughly 80 ng/mL at age sixty ^[3]. That is a real measured decline, and it is also a correlation — no study in this record demonstrates that restoring the level restores the phenotype.

Copper Tripeptide-1: The INCI Name and What It Signals

copper tripeptide-1 is the INCI name — the standardised cosmetic-ingredient label — for GHK-Cu. Seeing it on a carton signals a legal cosmetic ingredient with a long shelf history, and nothing more: there is no approved therapeutic indication for GHK-Cu by any route, in any jurisdiction. The INCI listing is a labelling convention, not an efficacy finding.

What a Copper Peptide Is, and Why the Copper Matters

copper peptide is the category; GHK-Cu is the specific molecule. The distinction that matters inside the category is the metal, and the distinction the literature keeps blurring is GHK versus GHK-Cu.

Free GHK is the bare tripeptide: molecular weight 340.38 Da, CAS 49557-75-7. GHK-Cu is the copper(II) chelate: molecular weight 402.92 Da, CAS 89030-95-5, formula C14H23CuN6O4+. The copper is held by the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen, leaving the lysine side chain free. The stability constant is high, log K around 16.4 — tight enough that the complex does not casually shed copper as a pro-oxidant.

Copper coordination is required for most of the documented tissue-repair activity. The free peptide does not reproduce MMP-2 stimulation in fibroblast cultures. So when a paper reports a systemic or gene-level effect, the first question is which form it used — and on the neuroprotection line the answer is awkward: the 2024 CNS work used GHK without copper, because the whole point of that mechanism is sequestering loose metal rather than delivering it ^[15].

Stability follows from the same chemistry. The complex is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio. Strong reducing agents — ascorbic acid below about pH 3.5 — reduce the Cu(II) and break the complex, and low-pH exfoliating acids can destabilise it or compete for the metal. A blue-violet solution is the expected Cu(II) absorption; brown or green means oxidation or precipitation, not an intact complex.

The neuroprotection line, stated at its actual strength

Four data points, and their tiers are not equal.

First preprint: 20-month-old C57BL/6 mice given intranasal GHK at 15 mg/kg daily for eight weeks scored better on the Y-maze (spatial memory) and the Box-maze (learning) than saline controls, with lower NFL-1 — a marker released when axons are damaged — in both sexes, and lower MCP-1, a neuroinflammation marker, in female frontal cortex ^[7].

Second preprint: 5xFAD transgenic mice, an aggressive Alzheimer model, given intranasal GHK at 15 mg/kg three times weekly for twelve weeks improved on both mazes, showed reduced amyloid plaque burden in frontal cortex and hippocampus, and lower MCP-1 ^[8]. Both papers are bioRxiv preprints. They have not been through peer review, and they come from the same group.

Third, a peer-reviewed mechanism: in 2024, GHK applied directly to cultured CNS neurons, microglia and astrocytes prevented copper- and zinc-induced protein aggregation and cell death by sequestering extracellular copper and blocking intracellular accumulation, completely preventing copper-induced DLAT aggregation, a marker of cuproptosis ^[15]. Fourth, a 2023 chemistry paper showing a biotinylated GHK and its copper complex inhibiting copper-induced ascorbate oxidation and protecting against amyloid-beta/acrolein adducts at 0-30 uM in cell-free assays ^[9].

Adjacent rodent behavioural work exists — GHK and analogues reduced anxiety-like behaviour in rats ^[10], and the tripeptide lowered attack frequency in a pain-induced aggression model ^[12]. That is the whole of it. Zero human neurological trials, no validated human pharmacokinetics, no CNS-distribution data. The full GHK-Cu neuroprotection research reading, with the routes and the caveats, is on the research page.

What the dermal record actually establishes

The skin literature is older, larger and better replicated than the CNS line, and it is where the confident numbers live.

In human fibroblast culture, collagen synthesis began rising between 10^-12 and 10^-11 M, peaked near 10^-9 M, and occurred with no change in cell number — the cells were not multiplying, they were manufacturing ^[1]. That dose curve is unusual: the effect is picomolar-to-nanomolar and does not simply scale upward with concentration.

Beyond collagen, the reviewed record reports synthesis of dermatan sulfate, chondroitin sulfate and the collagen-organising proteoglycan decorin, with placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density ^[3]. The most-quoted comparative figure sits here too: topical GHK-Cu increased collagen production in 70% of treated women, against 50% for vitamin C and 40% for retinoic acid ^[3], a comparison the 2025 anti-wrinkle review repeats ^[14].

Delivery is the constraint. Free GHK has a clogP of -2.24, meaning it is highly water-loving and passes poorly through the oily stratum corneum ^[14]. What does get through forms a reservoir: over 48 hours, about 136.2 ug/cm^2 of copper permeated dermatomed human skin and about 97 ug/cm^2 was retained as a dermal depot, with a permeability coefficient of 2.43 x 10^-4 cm/h ^[5].

The follicle branch of the same literature is set out at copper peptide hair growth, and the reported upsides and downsides at copper peptide benefits.

The gene-expression claim, and what it does and does not say

A 2018 analysis reported that GHK modulates expression of about 31.2% of human genes at a 50%-or-greater change threshold, raising 59% and suppressing 41%, with the ubiquitin-proteasome system — the cell's protein-disposal machinery — showing the sharpest single signature at 41 genes up and one down, alongside DNA-repair and antioxidant gene sets ^[2].

Two caveats travel with that figure and belong next to it every time it is quoted. The widely circulated "~4,000 genes" number is an extrapolation; the table at the stated threshold covers on the order of 2,100 genes ^[2]. And the signature derives largely from Connectivity Map analyses — a database of expression signatures — which await protein-level in vivo validation.

A third caveat is structural rather than statistical: a large share of the foundational GHK-Cu mechanistic and review literature originates with a single investigator and colleagues, so independent replication of the broader gene-expression and anti-aging claims is limited. That does not make the findings wrong. It does mean the record has less redundancy than its citation count suggests. Every source used here is listed in the GHK-Cu study index.